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Healthcare and 4) Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT, USAAbstractThe objective of this study was to compare the aetiologic yield of standard-of-care microbiologic testing ordered by physicians with that of a
multiplex PCR platform. Stool specimens obtained from children and young adults with gastrointestinal illness were evaluated by standard
laboratory methods and a developmental version of the FilmArray Gastrointestinal (GI) Diagnostic System (FilmArray GI Panel), a rapid
multiplex PCR platform that detects 23 bacterial, viral and protozoal agents. Results were classiﬁed according to the microbiologic tests
requested by the treating physician. A median of three (range 1–10) microbiologic tests were performed by the clinical laboratory during
378 unique diarrhoeal episodes. A potential aetiologic agent was identiﬁed in 46% of stool specimens by standard laboratory methods
and in 65% of specimens tested using the FilmArray GI Panel (p < 0.001). For those patients who only had Clostridium difﬁcile testing
requested, an alternative pathogen was identiﬁed in 29% of cases with the FilmArray GI Panel. Notably, 11 (12%) cases of norovirus
were identiﬁed among children who only had testing for Clostridium difﬁcile ordered. Among those who had C. difﬁcile testing ordered in
combination with other tests, an additional pathogen was identiﬁed in 57% of stool specimens with the FilmArray GI Panel. For patients
who had no C. difﬁcile testing performed, the FilmArray GI Panel identiﬁed a pathogen in 63% of cases, including C. difﬁcile in 8%.
Physician-speciﬁed laboratory testing may miss important diarrhoeal pathogens. Additionally, standard laboratory testing is likely to
underestimate co-infections with multiple infectious diarrhoeagenic agents.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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E-mail: Chris.Stockmann@hsc.utah.eduIntroductionDespite advances in sanitation, food safety, and immunization,
diarrhoeal diseases continue to cause substantial disease and
mortality in children living in both high- and low-resourceClinical Microbiology and Infection © 2014 European Society of Csettings [1,2]. A 2011 report from the United States Centers
for Disease Control and Prevention estimated that 178.8
million acute diarrhoeal illnesses occur annually in the United
States, resulting in 473 832 hospitalizations and 5072 deaths [3].
The changing epidemiology and ongoing outbreaks of old and
emerging pathogens including Clostridium difﬁcile, Cryptospo-
ridium spp., Cyclospora spp. and diarrhoeagenic Escherichia coli
underscore the need for accurate diagnostics and improved
surveillance for infectious diarrhoea [4,5].
Correctly diagnosing the aetiology of infectious diarrhoea
can improve clinical care and public health surveillance [6]. One
major obstacle in diagnosing infectious diarrhoea is the largeClin Microbiol Infect 2015; 21: 179.e9–179.e15
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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recognized to cause diarrhoea. Testing for speciﬁc pathogens is
complex, requiring a variety of methods. Clinicians must
choose the appropriate test, but this is challenging because of
substantial overlap in clinical and epidemiologic features.
Testing therefore can be expensive and inefﬁcient. For some
important pathogens such as diarrhoeagenic Escherichia coli,
norovirus and sapovirus, testing is not readily available. To
address this, there has been interest in developing multiplex
platforms that can simultaneously detect a range of diarrhoeal
pathogens [7–12].
The objective of this study was to compare the diagnostic
yield of standard microbiologic testing ordered by the treating
physician with the FilmArray Gastrointestinal Diagnostic Sys-
tem (FilmArray GI Panel, BioFire Diagnostics Inc., Salt Lake
City, UT), a multiplex polymerase chain reaction (PCR) system
that simultaneously detects 23 diarrhoeal pathogens. We hy-
pothesized that physician-speciﬁed microbiologic testing would
not accurately predict the pathogens present.
MethodsHuman subjects protection
This study was approved and granted a waiver of informed
consent by the University of Utah and Intermountain Health-
care (Intermountain) Institutional Review Boards (IRB #45464).
Setting and study population
Stool samples were collected from children and young adults
1–25 years of age with symptoms of acute gastrointestinal
illness (e.g. fever, vomiting, abdominal pain, and diarrhoea) who
received medical care at Primary Children’s Hospital. Stool
specimens that conformed to the shape of the cup were sub-
mitted for standard laboratory testing at the request of the
treating physician, and residual samples were stored frozen
at −80°C until tested with the FilmArray GI Panel. We
collected specimens from August 2010 through December
2012.
Of 1504 diarrhoeal episodes, 378 episodes were selected for
this study. This convenience sample was based on adequate
residual specimen volume and was enriched for those who had
multiple standard laboratory tests, including C. difﬁcile testing,
and for patients in whom a pathogen was detected. We
designed a sampling scheme based on the number of standard
laboratory tests ordered. We randomly selected 125 specimens
that had one standard laboratory test ordered, 118 specimens
that had two or three tests ordered, and 135 that had four or
more tests ordered. A single stool specimen from each of the
378 episodes was tested with the FilmArray GI Panel. AllClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectmicrobiologic results from physician-ordered tests performed
within ±72 hours of the collection of the specimen tested using
the FilmArray GI Panel were included in the analysis. The se-
lection of specimens for inclusion in this study was designed to
evaluate the potential impact of a multiplex, PCR-based diag-
nostic platform in comparison with physician-speciﬁed standard
laboratory testing and not to describe the epidemiology of
diarrhoea.
Standard laboratory testing
Standard laboratory testing was performed at the discretion of
the treating physician. Routine stool cultures identiﬁed Salmo-
nella spp., Shigella spp., Aeromonas spp., E. coli O157:H7 and
O121, Bacillus cereus, and Campylobacter jejuni and Campylo-
bacter coli using trypticase soy agar, MacConkey II agar, sorbitol
MacConkey agar, Hektoen Enteric agar, and Campy cefoper-
azone, vancomycin, and amphotericin B (CVA) agar. When
Yersinia enterocolitica testing was ordered, stool was plated on
cefsulodin– irgasan–novobiocin (CIN) agar. C. difﬁcile was
detected using the Illumigene C. difﬁcile ampliﬁcation assay
(Meridian Bioscience, Inc., Cincinnati, OH). Rotavirus and
adenovirus F 40/41 were detected using commercial immuno-
assays (Immunocard STAT!® Rotavirus and Meridian Premier™
Adenoclone®, Meridian Bioscience, Inc.). Shiga toxin-producing
E. coli (STEC) was sought for all bloody specimens and when
requested using a rapid immunoassay for Shiga toxin (Meridian
Premier™ EHEC, Meridian Bioscience, Inc.) on specimens
grown 24 hours in nutrient broth. Giardia lamblia and Crypto-
sporidium parvum were detected using the MERIFLUOR antigen
detection immunoassay (Meridian Bioscience, Inc.). Other
protozoa were identiﬁed by routine ova and parasite exami-
nation when requested. Laboratory testing for norovirus by
PCR was introduced during the last 6 months of the study;
however, norovirus testing was not ordered by the physician
for any of the specimens evaluated in this study. No standard
laboratory tests were available for the detection of astrovirus
or sapovirus.
FilmArray GI panel pathogen detection
The FilmArray rapid multiplex PCR platform [13,14] used in
this study was a developmental version of the FilmArray GI
Panel, which simultaneously detects 23 diarrhoeagenic bacte-
rial, viral, and protozoal agents in <1 hour (Table 1) using
pathogen-speciﬁc virulence genes or gene signatures in house-
keeping genes. Identiﬁcation of C. difﬁcile was based upon
detection of the genes that encode an enterotoxin (tcdA) and a
cytotoxin (tcdB). The pathotypes of pathogenic E. coli were
identiﬁed using pathotype-speciﬁc genetic markers: STEC by
detection of Shiga toxin 1 or 2 genes (stx1 or stx2), entero-
pathogenic E. coli (EPEC) by detection of the intimin gene (eae),ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 179.e9–179.e15
TABLE 1. Detection of bacterial, viral, and parasitic diarrhoeal
pathogens from 378 paediatric stool specimens evaluated by










Clostridium difﬁcile 77/273 (28%) 83/378 (22%)
EPEC NA 37/378 (10%)
All STEC 19/193 (10%) 30/378 (8%)
Escherichia coli O157 12/193 (7%) 18/378 (5%)
Non-O157 7/193 (4%) 12/378 (3%)
Salmonella spp. 24/189 (13%) 27/378 (7%)
Campylobacter spp. 6/189 (3%) 15/378 (4%)
Shigella/EIEC 5/189 (3%) 11/378 (3%)
EAEC NA 10/378 (3%)
Aeromonas spp. 2/189 (1%) 9/378 (2%)
ETEC NA 7/378 (2%)
Yersinia enterocolitica 0/36 (0%) 2/378 (1%)
Plesiomonas shigelloides 0/0 (0%) 1/378 (<1%)
Vibrio cholerae 0/0 (0%) 1/378 (<1%)
Viral pathogens
Norovirus GI/GII 0/0 (0%) 43/378 (11%)
Adenovirus F 40/41 6/73 (8%) 16/378 (4%)
Rotavirus A 17/98 (17%) 16/378 (4%)
Sapovirus NA 11/378 (3%)
Astrovirus NA 8/378 (2%)
Parasitic pathogens
Giardia lamblia 11/125 (9%) 18/378 (5%)
Cryptosporidium spp. 2/118 (2%) 6/378 (2%)
Cyclospora cayetanensis 0/0 (0%) 0/378 (0%)
Entamoeba histolytica 0/0 (0%) 0/378 (0%)
EAEC, enteroaggregative Escherichia coli; EIEC, enteroinvasive E. coli; EPEC,
enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; GI, gastrointestinal; NA,
standard laboratory testing not available; STEC, Shiga toxigenic E. coli.
CMI Stockmann et al. Insights using multiplex PCR-based detection 179.e11enterotoxigenic E. coli (ETEC) by genes encoding heat-labile (lt)
or heat-stable (st) enterotoxin, enteroinvasive E. coli and Shigella
by the invasion plasmid antigen H gene (ipah) and enter-
oaggregative E. coli (EAEC) by pAA virulence plasmid carried
genes encoding the aggregative adhesion ﬁmbria (AAF)
biogenesis transcription regulator (aggR) or outer membrane
protein (aatA). The FilmArray GI Panel identiﬁes Salmonella
spp., Aeromonas spp., Cryptosporidium spp., and pathogenic
species of Vibrio and Campylobacter (V. cholerae,
V. parahaemolyticus, V. vulniﬁcus, V. mimicus, V. alginolyticus,
V. ﬂuvialis, C. jejuni, C. coli and C. upsaliensis). Extensive perfor-
mance evaluation of the developmental version of the FilmAr-
ray GI Panel was conducted on 1721 clinical specimens and has
been reported previously [15]. FilmArray testing was per-
formed while blinded to standard testing results and patient
characteristics.
Statistical analysis
To characterize ﬁndings by physician ordering practice, we
divided patients into three groups for the analysis: i) those for
whom the physician ordered testing only for C. difﬁcile; ii) those
for whom testing was ordered for C. difﬁcile and other patho-
gens; and iii) those for whom testing was ordered only for
pathogens other than C. difﬁcile. Descriptive statistics were used
to characterize the study population and microbiologic testingClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infresults. Rates and proportions were compared using the χ2 test
or Fisher’s exact test, as appropriate. Nonparametric data were
compared using the Wilcoxon rank sum test. Alpha was set
equal to 0.05; all p-values are two-sided. Analyses were per-
formed in Stata 11.2 (StataCorp LP, College Station, TX) and
R 3.0 (R Foundation for Statistical Computing, Vienna, Austria).
To assess the concordance between standard laboratory
testing and the FilmArray GI Panel, we evaluated the sensitivity,
speciﬁcity, positive predictive value, and negative predictive
value for C. difﬁcile, rotavirus, Salmonella and STEC using
specimens tested by both methods.ResultsPatient characteristics
FilmArray testing was performed on stool specimens submitted
during 378 diarrhoeal episodes at Primary Children’s Hospital
from August of 2010 through December of 2012. There were
339 unique patients with a median age of 6 (interquartile range
(IQR) 3–12) years (40% were <5 years of age); 58% were male.
The majority were White (77%), Hispanic (11%), and Black (4%).
Patient encounters occurred in the outpatient setting (68%),
inpatient setting (20%), and the emergency department (12%).
Standard laboratory testing
A median of three (range 1–10) tests were ordered for each
diarrhoeal episode. A gastrointestinal pathogen was detected by
standard laboratory methods in 175 (46%) of 378 diarrhoeal
episodes (Fig. 1). Co-infections were identiﬁed in 1.6% of
diarrhoeal episodes by standard laboratory methods. The most
commonly detected pathogens included: C. difﬁcile (77 of 273
tested; 28%), Salmonella (24/189; 13%), rotavirus (17/98; 17%)
and STEC (19/193; 10%).
The number of tests ordered varied according to the setting.
Outpatient encounters had the lowest number of tests ordered
(median 2; IQR 1–3), followed by emergency department visits
(median 3; IQR 2–4) and inpatient encounters (median 3; IQR
1–5). A pathogen was detected by standard laboratory
methods in 44% of outpatient encounters, 50% of emergency
department visits, and 46% of inpatient encounters. C. difﬁcile
was detected by standard laboratory testing in 22 of 64 (34%)
outpatients, 7 of 47 (15%) emergency department patients, and
48 of 162 (30%) inpatients.
FilmArray GI panel
When C. difﬁcile testing was performed upon the same spec-
imen using both standard laboratory methods and the FilmAr-
ray GI Panel, the sensitivity was 95% (95% CI 87–99%) and the
speciﬁcity was 99% (95% CI 96–100%).ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 179.e9–179.e15
TABLE 2. Diarrhoeal pathogens detected from paediatric
stool specimens collected in outpatient, emergency, and










Clostridium difﬁcile 25 (25%) 9 (12%) 49 (24%)
EPEC 10 (10%) 10 (13%) 17 (8%)
All STEC 7 (7%) 10 (13%) 13 (6%)
E. coli O157 4 (4%) 5 (7%) 9 (4%)
Non-O157 3 (3%) 5 (7%) 4 (2%)
Salmonella spp. 3 (3%) 14 (18%) 10 (5%)
Campylobacter spp. 5 (5%) 5 (7%) 5 (2%)
Shigella / EIEC 3 (3%) 4 (5%) 4 (2%)
EAEC 0 (0%) 6 (8%) 4 (2%)
Aeromonas spp. 3 (3%) 5 (7%) 1 (1%)
ETEC 2 (2%) 3 (4%) 2 (1%)
Yersinia enterocolitica 0 (0%) 0 (0%) 2 (1%)
Plesiomonas shigelloides 0 (0%) 0 (0%) 1 (1%)
Vibrio cholerae 1 (1%) 0 (0%) 0 (0%)
Viral pathogens
Norovirus GI/GII 13 (13%) 9 (12%) 21 (10%)
Adenovirus F 40/41 4 (4%) 5 (7%) 7 (3%)
Rotavirus A 1 (1%) 3 (4%) 12 (6%)
Sapovirus 3 (3%) 4 (5%) 4 (2%)
Astrovirus 1 (1%) 1 (1%) 6 (3%)
Parasitic pathogens
Giardia lamblia 9 (9%) 4 (5%) 5 (2%)
Cryptosporidium spp. 3 (3%) 2 (3%) 1 (1%)
Negative 37 (37%) 16 (21%) 81 (40%)
Numbers presented within cells are the number of positive specimens, and in
parentheses are the percentages for each diarrhoeal pathogen. Pathogens with no
detections in all three clinical settings are not featured in this table.
EAEC, enteroaggregative Escherichia coli; EIEC, enteroinvasive E. coli; EPEC,
enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; GI, gastrointestinal; NA,
standard laboratory testing not available; STEC, Shiga toxigenic E. coli.
FIG. 1. Clostridium difﬁcile and other diarrhoeal pathogens detected
from pediatric stool specimens tested by standard laboratory methods
and the FilmArray GI Panel. GI, gastrointestinal.
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378 (65%) diarrhoeal episodes (Table 1, Fig. 1). Multiple path-
ogens were detected in 77 (20%). The most common patho-
gens detected included C. difﬁcile (83/378; 22%), norovirus (43/
378; 11%), enteropathogenic E. coli (37/378; 10%) and STEC
(30/378; 8%).
The aetiologic agents detected varied based upon the
setting of the encounter (Table 2). C. difﬁcile was more
frequently detected among outpatients (25/100; 25%) and in-
patients (49/202; 24%) than from patients in the emergency
department (9/76; 12%) (p = 0.02). However, the overall
proportion of specimens with a pathogen identiﬁed did not
vary between the outpatient, emergency department, and
inpatient settings (p = 0.8).
Use of the FilmArray improved the diagnostic yield from
46% to 65% as compared to standard laboratory testing
methods (p < 0.001). Similar improvements were identiﬁed
among patients who had one, two or three, or four or more
standard laboratory tests ordered (18%, 23%, and 14%,
respectively).
Findings by physician test selection
Only C. difﬁcile testing requested. Standard laboratory testing for
C. difﬁcile was the only test ordered in 91 episodes (Fig. 2).
C. difﬁcile was detected by standard laboratory methods in 42Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectepisodes (46%) and by the FilmArray GI Panel in 40 (44%)
(p = 0.8). An additional pathogen was detected by FilmArray in
26 (29%), 11 (12%) as a co-infection with C. difﬁcile. Co-
detections among the 11 patients with C. difﬁcile included
seven with norovirus, one with Salmonella, and one with
Campylobacter spp. Pathogens detected among the 15 children
who tested negative for C. difﬁcile included norovirus (n = 4),
astrovirus (n = 2), sapovirus (n = 1), and G. lamblia (n = 1). In
this group, the proportion of episodes without an identiﬁed
pathogen declined from 54% to 40% using the FilmArray GI
Panel (p = 0.05).
The majority (59%) of stool samples in which only C. difﬁcile
testing was ordered were collected during inpatient encoun-
ters. Of these, 50% tested positive for C. difﬁcile by standard
laboratory methods. Similarly, 46% were positive for C. difﬁcile
using the FilmArray GI Panel, although an additional 19% had
another pathogen detected.
Among children who only had C. difﬁcile testing requested,
the greatest increase in pathogen detection was among children
1–4 years of age (n = 42). In this sub-group, 20/42 (48%)
children had C. difﬁcile detected by standard laboratory testing
methods, while 30/42 (71%) had a pathogen detected by the
FilmArray GI Panel (p = 0.03). The additional pathogens
detected included: norovirus (n = 7), EPEC (n = 3),ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 179.e9–179.e15
FIG. 2. Physician ordering patterns and
their impact upon diarrhoeal pathogen
detection from pediatric stool specimens
tested with standard laboratory methods
and the FilmArray GI Panel. GI,
gastrointestinal.
CMI Stockmann et al. Insights using multiplex PCR-based detection 179.e13Campylobacter (n = 2), sapovirus (n = 2), G. lamblia (n = 1) and
P. shigelloides (n = 1).
C. difﬁcile requested in combination with other tests. In 182 of 273
(67%) episodes, C. difﬁcile testing was requested along with one
or more additional tests. Of these, 51% had one or more
pathogens detected by standard laboratory tests, as compared
with 68% when tested with the FilmArray GI Panel (p < 0.001)
(Fig. 2). The most common pathogens detected using standard
laboratory tests were C. difﬁcile (35; 19%), Salmonella (15; 9%),
STEC (13; 7%) and rotavirus (9; 5%). Co-infections were
detected in four (2%) specimens. Using the FilmArray GI Panel,
C. difﬁcile was detected in 35 (19%), norovirus in 28 (15%),
EPEC in 22 (12%), STEC in 20 (11%) and Salmonella in 16 (9%).
In 15 of 35 (43%) patients in whom C. difﬁcile was detected, an
additional pathogen was also identiﬁed. The most common co-
infecting pathogens were norovirus (n = 7), EPEC (n = 5),
Campylobacter spp. (n = 2) and Salmonella (n = 1). When
C. difﬁcile was not detected, the FilmArray GI Panel detected a
pathogen in 60% (88/147), including norovirus (21/147; 14%),
STEC (20/147; 14%), Salmonella (15/147; 20%) and EPEC (17/
147; 12%). When compared with standard laboratory methods,
the proportion of specimens with more than one diarrhoeal
pathogen identiﬁed rose from 2% to 25% (p < 0.001).
Only tests other than C. difﬁcile requested. In 105 (28%) episodes
of diarrhoea, stool specimens were submitted for standard
laboratory testing for one or more diarrhoeal pathogens, but
did not have C. difﬁcile testing. Of these, 40 (38%) had a path-
ogen detected using standard laboratory testing methods. WithClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infthe FilmArray GI Panel, a pathogen was detected in 63%
(p < 0.001); multiple pathogens were detected in 18% (n = 19).
The most common pathogens detected by standard labora-
tory testing methods were G. lamblia (10/105; 10%), Salmonella
(8/105; 8%), rotavirus (7/105; 7%) and STEC (6/105; 6%). Using
the FilmArray GI Panel, G. lamblia (11/105; 10%), Salmonella
(10/105; 10%), STEC (10/105; 10%), C. difﬁcile (8/105; 8%) and
rotavirus (7/105; 7%) were the most common. The proportion
of specimens with multiple pathogens identiﬁed rose from 2%
to 18% (p < 0.001). The proportion of specimens that had a
pathogen identiﬁed did not signiﬁcantly differ by age (p = 0.07)
or patient location (p = 0.1).
DiscussionCorrectly diagnosing the aetiology of infectious diarrhoea de-
pends on both the physician’s decision to order the correct test
and the sensitivity of the testing method. In this study, we
compared the detection of infectious pathogens by physician-
selected standard tests to a multiplex PCR assay that simulta-
neously detects 23 bacterial, viral and protozoal pathogens. In
this sample, the identiﬁcation of a pathogen increased from 46%
of episodes to 65%. Co-detection of multiple diarrhoeal path-
ogens increased from 2% to 20%. Applying the FilmArray GI
Panel to patents that clinicians had decided warranted diag-
nostic testing identiﬁed 72 additional viral infections, including
43 cases of norovirus, 13 additional protozoal pathogens and
100 additional potential bacterial infections. The bacterialectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 179.e9–179.e15
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included many with clear clinical importance, including: 11
additional STEC, nine Campylobacter, seven Aeromonas, seven
ETEC, six Shigella, and six Salmonella. This study demonstrated
some limitations of physician-speciﬁed testing for patients with
diarrhoea. Among children in whom C. difﬁcile testing was not
ordered, 8% had C. difﬁcile detected using the FilmArray GI
Panel. Conversely, when only C. difﬁcile was sought, additional
pathogens were detected in 28%.
C. difﬁcile is an important and frequent cause of nosocomial
and antibiotic-associated diarrhoea in adults and is increasingly
recognized as an important pathogen among children [16–19].
Kim et al. reported a 53% increase in the incidence of C. difﬁcile
among 22 freestanding children’s hospitals across the United
States from 2001 to 2006 [20]. In a recent propensity-matched
cohort study, the morbidity and costs attributable to C. difﬁcile
infections in hospitalized children were substantial; $18 900 per
episode of community-onset C. difﬁcile infection and $93 600
for an episode of hospital-onset C. difﬁcile infection [21]. These
ﬁndings underscore the importance of detecting C. difﬁcile in a
variety of clinical settings. It is noteworthy that we detected
C. difﬁcile in 8% of diarrhoeal episodes where C. difﬁcile testing
was not sought.
To be useful, diagnostic tests for diarrhoeal pathogens should
positively affect clinical care, infection prevention and public
health [6]. Routine stool cultures identify a diarrhoeal pathogen
infrequently, with estimates from several studies ranging from
1.5% to 5.8% [22–24]. Use of the FilmArray GI Panel identiﬁed
a substantial number of additional bacterial infections for which
treatment may be helpful (nine Campylobacter, seven ETEC,
seven Aeromonas, six Shigella, two Y. enterocolitica and one Ple-
siomonas shigelloides) and where the use of antibiotics may be
undesirable (11 STEC and three Salmonella) (6).
Norovirus is the leading cause of foodborne disease out-
breaks and is increasingly recognized as a nosocomial pathogen,
sometimes mimicking C. difﬁcile [25–27]. With multiplex testing,
we identiﬁed norovirus in 11% of diarrhoeal episodes. Inter-
estingly, using the same CDC deﬁnitions designed for C. difﬁcile,
three hospital-onset cases of norovirus were identiﬁed, deﬁned
as detection more than 72 hours after admission. Routine
detection of norovirus could facilitate infection control efforts in
the hospital and outbreak detection in the community [27].
Limited data exist describing the extent to which co-
infections complicate the clinical presentation of paediatric
diarrhoea [28]. Tvede et al. evaluated 32 Swedish children who
were hospitalized with C. difﬁcile infection and found that 44%
were concurrently infected with another bacterial pathogen,
including Campylobacter spp., Salmonella, Y. enterocolitica and
E. coli [29]. In this study, 20% of specimens tested were positive
for two or more diarrhoeal pathogens using the FilmArray GIClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectPanel. Among patients with C. difﬁcile infection, 35% had at least
one additional diarrhoeal pathogen identiﬁed, including nor-
ovirus in 17%. It is unclear if these co-infections impacted dis-
ease severity.
We frequently detected genes associated with EPEC and
EAEC; however, detection of these genes may not prove that
they are present in a single organism. The complex molecular
pathogenesis and overlapping virulence genes complicates the
interpretation of pathogenic E. coli detection [30]. However, in
a case control study in a paediatric emergency room in Seattle,
Denno et al. demonstrated that EAEC was signiﬁcantly associ-
ated with acute diarrhoea [31].
The results of this study are subject to several limitations.
First, this was a convenience sample of diarrhoeal stool speci-
mens designed to look at test ordering patterns and was not a
random or sequential sample of diarrhoeal episodes. Therefore,
the detection of pathogens by standard methods was higher in
this study than would be expected in routine testing. For
example, in our clinical laboratory, a pathogen is identiﬁed in
about 12% of all specimens by routine physician-selected
testing, as compared with 46% in this study. Second, this
study was laboratory based and analysed de-identiﬁed samples;
therefore, limited clinical data were available for review. Most
importantly, no control group of asymptomatic patients was
included, making it impossible to establish whether detection of
a speciﬁc pathogen or co-infections with multiple diarrhoeal
pathogens was associated with disease.
The diagnosis and management of paediatric diarrhoea is
complicated, and current testing strategies are expensive and
inefﬁcient. Our data support the use of the FilmArray GI Panel
or other multiplex testing platforms to simultaneously detect a
wide spectrum of diarrhoeal pathogens. Future studies will
need to evaluate the clinical and epidemiologic utility, efﬁciency,
accuracy, and cost-effectiveness of multiplex molecular testing.Transparency DeclarationM.R., B.H., M.V., R.C., M.P. and S.T. are employees of BioFire
Diagnostics, Inc., the maker and manufacturer of the FilmArray
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